These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11433243)

  • 1. Evolving paradigms in biotech IPO valuations.
    Papadopoulos S
    Nat Biotechnol; 2001 Jul; 19 Suppl():BE18-9. PubMed ID: 11433243
    [No Abstract]   [Full Text] [Related]  

  • 2. Shutters come off IPO window.
    Hodgson J
    Nat Biotechnol; 2002 Jan; 20(1):6. PubMed ID: 11753342
    [No Abstract]   [Full Text] [Related]  

  • 3. Delisting threat looms large on biotech front.
    Lawrence S
    Nat Biotechnol; 2005 Jan; 23(1):5. PubMed ID: 15637598
    [No Abstract]   [Full Text] [Related]  

  • 4. Nasdaq dilutes its biotech index.
    Dorey E
    Nat Biotechnol; 2004 Jan; 22(1):9. PubMed ID: 14704690
    [No Abstract]   [Full Text] [Related]  

  • 5. State of the biotech sector - 2006.
    Lawrence S
    Nat Biotechnol; 2007 Jul; 25(7):706. PubMed ID: 17621283
    [No Abstract]   [Full Text] [Related]  

  • 6. PEGging biotech growth.
    Jacobs T
    Nat Biotechnol; 2006 May; 24(5):506. PubMed ID: 16680127
    [No Abstract]   [Full Text] [Related]  

  • 7. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 8. The number on biotech indexes.
    Jacobs T
    Nat Biotechnol; 2005 Nov; 23(11):1356. PubMed ID: 16273059
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 10. Tough times set to continue for US biotech start-ups.
    Lehrman S
    Nature; 1999 Jan; 397(6716):191. PubMed ID: 9930684
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech holds its own in Q2.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
    [No Abstract]   [Full Text] [Related]  

  • 12. US government previews biotech survey.
    Goho A
    Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
    [No Abstract]   [Full Text] [Related]  

  • 13. Is your biotech giving away the store?
    Jacobs T
    Nat Biotechnol; 2002 Nov; 20(11):1079. PubMed ID: 12410245
    [No Abstract]   [Full Text] [Related]  

  • 14. Getting real about valuations in biotech.
    Villiger R; Bogdan B
    Nat Biotechnol; 2005 Apr; 23(4):423-8. PubMed ID: 15815665
    [No Abstract]   [Full Text] [Related]  

  • 15. Hwang scandal hits Korean biotech hard.
    Fuyuno I
    Nature; 2006 Jan; 439(7074):265. PubMed ID: 16421542
    [No Abstract]   [Full Text] [Related]  

  • 16. Scientists and societies. The Polish biotech gap.
    Gorlach S; Slabicki M
    Nature; 2004 Feb; 427(6977):870. PubMed ID: 14985771
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 18. John McCamant on the future of biotech. Interview by Dennis Murray.
    McCamant J
    Med Econ; 2002 Jan; 79(1):43-6. PubMed ID: 11807995
    [No Abstract]   [Full Text] [Related]  

  • 19. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 20. Australian biotech suffers growing pains.
    O'Neill G
    Nat Biotechnol; 2005 Apr; 23(4):401-2. PubMed ID: 15815652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.